NO20171457A1 - Effervescent lozenge - Google Patents
Effervescent lozenge Download PDFInfo
- Publication number
- NO20171457A1 NO20171457A1 NO20171457A NO20171457A NO20171457A1 NO 20171457 A1 NO20171457 A1 NO 20171457A1 NO 20171457 A NO20171457 A NO 20171457A NO 20171457 A NO20171457 A NO 20171457A NO 20171457 A1 NO20171457 A1 NO 20171457A1
- Authority
- NO
- Norway
- Prior art keywords
- effervescent
- intact
- lozenge
- mixture
- active ingredient
- Prior art date
Links
- 239000007937 lozenge Substances 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 29
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 58
- 239000004480 active ingredient Substances 0.000 claims description 25
- 229960005070 ascorbic acid Drugs 0.000 claims description 23
- 235000010323 ascorbic acid Nutrition 0.000 claims description 22
- 239000011668 ascorbic acid Substances 0.000 claims description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 9
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 5
- 201000007100 Pharyngitis Diseases 0.000 claims description 5
- 206010043521 Throat irritation Diseases 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 239000007938 effervescent tablet Substances 0.000 abstract description 25
- 239000013543 active substance Substances 0.000 abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 210000000214 mouth Anatomy 0.000 description 12
- 210000003097 mucus Anatomy 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 210000003800 pharynx Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 235000021537 Beetroot Nutrition 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- ORXJMBXYSGGCHG-UHFFFAOYSA-N dimethyl 2-methoxypropanedioate Chemical compound COC(=O)C(OC)C(=O)OC ORXJMBXYSGGCHG-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
Anvendelse av en effervesent blanding for fremstilling av en intakt effervesent sugetablett, hvor den intakte effervesente tabletten inneholder et virkestoff, og hvor den den intakte effervesente tabletten administreres oralt.Use of an effervescent composition for the preparation of an intact effervescent lozenge, wherein the intact effervescent tablet contains an active substance and wherein the intact effervescent tablet is administered orally.
Description
EFFERVESENT SUGETABLETT EFFERVESENT LOGGING TABLET
Oppfinnelsen vedrører en effervesent tablett. En effervesent tablett er også kjent som en brusetablett. Mer spesifikt vedrører oppfinnelsen en effervesent tablett som i sammensetning og størrelse er tilpasset til å administreres oralt som en intakt tablett. Tablettens effervesente virkning oppnås ved at brukeren suger på tabletten i munnhulen. Enda mer spesifikt vedrører oppfinnelsen en effervesent tablett som omfatter et virkestoff. Virkestoffet kan være et vitamin. Virkestoffet kan være en antioksidant. Virkestoffet kan være et antibiotika. Virkestoffet kan være en anti-virus substans. Virkestoffet kan være et legemiddel for opptak i en slimhinne eller gjennom en slimhinne. The invention relates to an effervescent tablet. An effervescent tablet is also known as an effervescent tablet. More specifically, the invention relates to an effervescent tablet which in composition and size is adapted to be administered orally as an intact tablet. The tablet's effervescent effect is achieved by the user sucking on the tablet in the oral cavity. Even more specifically, the invention relates to an effervescent tablet comprising an active ingredient. The active ingredient can be a vitamin. The active ingredient can be an antioxidant. The active ingredient can be an antibiotic. The active ingredient can be an anti-virus substance. The active ingredient can be a medicine for absorption in a mucous membrane or through a mucous membrane.
Brusetabletter som inneholder C-vitamin, er tilpasset til å løses opp i vann før den flytende C-vitaminblandingen drikkes. Det er også kjent å anvende legemidler formulert som effervesente tabletter. Slike legemidler administreres ved først å løse den effervesente tabletten opp i en passende mengde vann eller vannholdig væske. Væsken med det oppløste legemidlet administreres så oralt ved at den flytende blandingen drikkes. Patentskrift WO 2014/160872 lærer en brusetablett som inneholder bordsalt. Den oppløste blandingen skal deretter gurgles men helst ikke svelges. Effervescent tablets containing vitamin C are adapted to be dissolved in water before drinking the liquid vitamin C mixture. It is also known to use drugs formulated as effervescent tablets. Such drugs are administered by first dissolving the effervescent tablet in an appropriate amount of water or aqueous liquid. The liquid with the dissolved drug is then administered orally by drinking the liquid mixture. Patent document WO 2014/160872 teaches an effervescent tablet containing table salt. The dissolved mixture should then be gargled but preferably not swallowed.
Begynnende forkjølelse merkes ved en kløende eller ubehagelig følelse i minst en av munnhule og svelg. Svelg omfatter farynks. Vanligvis skyldes kløen eller den ubehagelige følelsen en virusinfeksjon, men det kan også skyldes en bakterieinfeksjon. Cellene i munnhule og svelg er dekket med et slim som danner et beskyttende lag for cellene. Slimet er vannholdig. Slimet vil også beskytte virus og bakterier i og på cellene i munnhule og svelg. Virusinfeksjonen eller bakterieinfeksjonen vil også stimulere cellene til å produsere mer slim. The onset of a cold is felt by an itchy or unpleasant sensation in at least one of the oral cavity and pharynx. Pharynx includes pharynx. Usually the itching or discomfort is caused by a viral infection, but it can also be caused by a bacterial infection. The cells in the oral cavity and pharynx are covered with a mucus that forms a protective layer for the cells. The mucus is watery. The mucus will also protect viruses and bacteria in and on the cells in the oral cavity and throat. The viral or bacterial infection will also stimulate the cells to produce more mucus.
Det er vanskelig å behandle infeksjoner i munnhule og spesielt infeksjoner i svelg, med topisk administrering av ett eller flere virkestoffer. Det er kjent å anvende sugetabletter og drops med virkestoffer mot forkjølelse, men slike sugetabletter og drops gir kun en lindrende virkning eller en opplevd lindrende virkning. Sugetabletter og drops er formulert til å være vannoppløselige siden de oppløses i et spytt. Slimlaget i munnhule og svelg beskytter de underliggende cellene mot virkestoffene i slike sugetabletter og drops og virkestoffene når ikke fram til cellene eller til virus og bakterier som er på utsiden av cellene. It is difficult to treat infections in the oral cavity and especially infections in the pharynx, with topical administration of one or more active substances. It is known to use lozenges and drops with active ingredients against colds, but such lozenges and drops only provide a soothing effect or a perceived soothing effect. Lozenges and drops are formulated to be water-soluble since they dissolve in saliva. The mucus layer in the oral cavity and pharynx protects the underlying cells from the active substances in such lozenges and drops, and the active substances do not reach the cells or viruses and bacteria that are on the outside of the cells.
Oppfinnelsen har til formål å avhjelpe eller å redusere i det minste én av ulempene ved kjent teknikk, eller i det minste å skaffe til veie et nyttig alternativ til kjent teknikk. The purpose of the invention is to remedy or to reduce at least one of the disadvantages of known technology, or at least to provide a useful alternative to known technology.
P28090NO01 beskrivelse og krav, prioritetsdannende med prioritet P28090NO01 description and requirements, priority forming with priority
Formålet oppnås ved trekkene som er angitt i nedenstående beskrivelse og i de etterfølgende patentkravene. The purpose is achieved by the features indicated in the description below and in the subsequent patent claims.
En effervesent blanding av en syre, spesielt en organisk syre, og en base, spesielt et karbonat, utvikler CO2-gass når syren og basen reagerer med vann. En effervesent tablett inneholder en effervesent blanding. An effervescent mixture of an acid, especially an organic acid, and a base, especially a carbonate, evolves CO2 gas when the acid and base react with water. An effervescent tablet contains an effervescent mixture.
En effervesent tablett som administreres oralt ved at den føres intakt inn i en munnhule for at brukeren skal suge og eventuelt tygge på den effervesente tabletten, vil utvikle CO2-gass når den effervesente blandingen reagerer det fuktige slimlaget i munnhule og svelg. Det fuktige slimlaget inneholder vann. An effervescent tablet administered orally by inserting it intact into an oral cavity for the user to suck and possibly chew on the effervescent tablet will develop CO2 gas when the effervescent mixture reacts with the moist mucus layer in the oral cavity and pharynx. The moist mucus layer contains water.
Oppfinneren vil ikke bindes av følgende som teori: Fuktigheten i slimlaget som reagerer med den effervesente blandingen, vil trekkes ut av slimlaget, og slimlaget kan svekkes av dette. Slimlaget vil også kunne løsne fra de underliggende cellene på grunn av CO2-gassen som frigjøres, og som vil ha en mekanisk påvirkning på slimlaget. Den effervesente tabletten som suges i munnhulen, omfatter et virkestoff. Virkestoffet vil komme i topisk kontakt med cellene under slimlaget der slimlaget er svekket eller løsnet. Et virkestoff som har effekt mot et virus, en bakterie eller som har effekt mot virus og bakterier, vil kunne få en økt effekt mot virus og bakterier utenpå cellene, da disse virus og bakterier vil eksponeres direkte for virkestoffet. Cellene vil også kunne ta opp virkestoffet over cellemembranen. The inventor will not be bound by the following as theory: The moisture in the slime layer that reacts with the effervescent mixture will be drawn out of the slime layer, and the slime layer may be weakened by this. The mucus layer will also be able to detach from the underlying cells due to the CO2 gas that is released, which will have a mechanical effect on the mucus layer. The effervescent tablet that is sucked into the oral cavity contains an active ingredient. The active substance will come into topical contact with the cells under the mucus layer where the mucus layer is weakened or loosened. An active substance that has an effect against a virus, a bacterium or that has an effect against viruses and bacteria will be able to have an increased effect against viruses and bacteria outside the cells, as these viruses and bacteria will be exposed directly to the active substance. The cells will also be able to absorb the active ingredient across the cell membrane.
Kjente brusetabletter som omfatter et virkestoff, og som løses i vann eller en vandig væske før oral administrering, vil ikke gi samme virkning. Væsken som drikkes, vil ikke påvirke vannet i slimlaget i munnhule og svelg. Den effervesente blandingen i brusetabletten vil reagere med vannet i væsken. Dette vannet er fritt tilgjengelig i motsetning til vannet i et fuktig slimlag. Den orale administrasjonsformen i henhold til foreliggende oppfinnelse skiller seg derfor vesentlig fra den orale administrasjonsformen hvor preparatet først løses i vann eller vannholdig væske og deretter drikkes. Known effervescent tablets which include an active substance and which are dissolved in water or an aqueous liquid before oral administration, will not produce the same effect. The liquid that is drunk will not affect the water in the mucous layer in the oral cavity and pharynx. The effervescent mixture in the effervescent tablet will react with the water in the liquid. This water is freely available, unlike the water in a moist mucus layer. The oral administration form according to the present invention therefore differs significantly from the oral administration form where the preparation is first dissolved in water or an aqueous liquid and then drunk.
Virkestoffet kan være et vitamin. Vitaminet kan være et C-vitamin. Virkestoffet kan være en antioksidant. Virkestoffet kan være et antibiotika. Virkestoffet kan være et anti-virus middel. Virkestoffet kan være et legemiddel for opptak i en slimhinne. Virkestoffet kan være et legemiddel for opptak gjennom en slimhinne. Virkestoffet kan være et legemiddel for behandling av en slimhinne. Den effervesente tabletten kan inneholde en blanding av en flerhet av virkestoffer. The active ingredient can be a vitamin. The vitamin can be a C vitamin. The active ingredient can be an antioxidant. The active ingredient can be an antibiotic. The active ingredient can be an anti-virus agent. The active ingredient can be a medicine for absorption in a mucous membrane. The active ingredient can be a medicine for absorption through a mucous membrane. The active substance can be a medicine for the treatment of a mucous membrane. The effervescent tablet may contain a mixture of a plurality of active substances.
Som eksempel nevnes at en brusetablett som inneholder C-vitamin, vil danne en drikkbar væske når brusetabletten oppløses i vann eller vannholdig væske. C-vitaminet vil være løst i vannet eller væsken. Virus og bakterier i munnhule og svelg vil ikke direkte påvirkes av C-vitaminet i den vannet eller væsken når den vannet eller væsken administreres oralt. As an example, an effervescent tablet containing vitamin C will form a drinkable liquid when the effervescent tablet is dissolved in water or an aqueous liquid. The vitamin C will be dissolved in the water or liquid. Viruses and bacteria in the oral cavity and pharynx will not be directly affected by the vitamin C in that water or liquid when that water or liquid is administered orally.
Den effervesente tabletten i henhold til oppfinnelsen er formulert slik at brukeren opplever en akseptabel munnfølelse når brukeren suger og/eller tygger på den intakte effervesente tabletten. The effervescent tablet according to the invention is formulated so that the user experiences an acceptable mouthfeel when the user sucks and/or chews on the intact effervescent tablet.
P28090NO01 beskrivelse og krav, prioritetsdannende med prioritet P28090NO01 description and requirements, priority forming with priority
Med intakt effervesent tablett menes at tabletten ikke har vært eksponert for vann eller vannholdig væske før oral administrasjon. Den effervesente tabletten kan være forsynt med bruddanvisning for at en bruker skal kunne dele den effervesente tabletten opp i mindre stykker. Slike mindre stykker utgjør også en intakt tablett. Med intakt tablett menes med andre ord at tabletten er tørr ved innføring av tabletten eller stykker av tabletten i munnen. An intact effervescent tablet means that the tablet has not been exposed to water or an aqueous liquid prior to oral administration. The effervescent tablet may be provided with breaking instructions so that a user can divide the effervescent tablet into smaller pieces. Such smaller pieces also make up an intact tablet. In other words, an intact tablet means that the tablet is dry when the tablet or pieces of the tablet are placed in the mouth.
Oppfinnelsen er definert av det selvstendige patentkravet. De uselvstendige kravene definerer fordelaktige utførelser av oppfinnelsen. The invention is defined by the independent patent claim. The independent claims define advantageous embodiments of the invention.
I et første aspekt vedrører oppfinnelsen mer spesifikt en anvendelse av en effervesent blanding for fremstilling av en intakt effervesent sugetablett, hvor den intakte effervesente sugetabletten inneholder et virkestoff, og hvor den den intakte effervesente sugetabletten administreres oralt. Den effervesente blandingen kan omfatte en farmasøytisk akseptabel blanding av en syre og en base. Syren kan omfatte en farmasøytisk akseptabel organisk syre eller en farmasøytisk akseptabel forbindelse av den farmasøytisk akseptable organiske syren. Basen kan være en karbonatbase. Karbonatbasen kan omfatte i det minste natriumbikarbonat. Mengdeforholdet (vekt/vekt) mellom den organiske syren eller den farmasøytisk akseptable forbindelsen av den farmasøytisk akseptable organiske syren og natriumbikarbonat kan være fra 1:2 til 2:1. In a first aspect, the invention relates more specifically to the use of an effervescent mixture for the production of an intact effervescent lozenge, where the intact effervescent lozenge contains an active ingredient, and where the intact effervescent lozenge is administered orally. The effervescent mixture may comprise a pharmaceutically acceptable mixture of an acid and a base. The acid may comprise a pharmaceutically acceptable organic acid or a pharmaceutically acceptable compound of the pharmaceutically acceptable organic acid. The base can be a carbonate base. The carbonate base may comprise at least sodium bicarbonate. The amount ratio (w/w) between the organic acid or the pharmaceutically acceptable compound of the pharmaceutically acceptable organic acid and sodium bicarbonate may be from 1:2 to 2:1.
Virkestoffet kan omfatte en askorbinsyre eller en farmasøytisk akseptabel forbindelse av askorbinsyre for forebygging eller lindring av en kløende hals. Virkestoffet kan omfatte en askorbinsyre eller en farmasøytisk akseptabel forbindelse av askorbinsyre for forebygging av en sår hals. Virkestoffet kan omfatte en askorbinsyre eller en farmasøytisk akseptabel forbindelse av askorbinsyre for forebygging av et kløende svelg. Virkestoffet kan omfatte en askorbinsyre eller en farmasøytisk akseptabel forbindelse av askorbinsyre for lindring av en sår hals. Virkestoffet kan omfatte en askorbinsyre eller en farmasøytisk akseptabel forbindelse av askorbinsyre for lindring av et sårt svelg. The active ingredient may comprise an ascorbic acid or a pharmaceutically acceptable compound of ascorbic acid for the prevention or relief of an itchy throat. The active substance may comprise an ascorbic acid or a pharmaceutically acceptable compound of ascorbic acid for the prevention of a sore throat. The active substance may comprise an ascorbic acid or a pharmaceutically acceptable compound of ascorbic acid for the prevention of an itchy throat. The active ingredient may comprise an ascorbic acid or a pharmaceutically acceptable compound of ascorbic acid for the relief of a sore throat. The active substance may comprise an ascorbic acid or a pharmaceutically acceptable compound of ascorbic acid for the relief of a sore throat.
Askorbinsyren eller den farmasøytisk akseptable forbindelsen av askorbinsyren kan utgjøre fra 10 vektprosent til 50 vektprosent av den intakte effervesente sugetabletten. The ascorbic acid or the pharmaceutically acceptable compound of the ascorbic acid may constitute from 10 weight percent to 50 weight percent of the intact effervescent lozenge.
Virkestoffet kan omfatte en antioksidant. Virkestoffet kan omfatte et antibiotikum. Virkestoffet kan omfatte et anti-virus middel. The active ingredient may comprise an antioxidant. The active ingredient may include an antibiotic. The active substance may comprise an anti-virus agent.
En syre i den effervesente blandingen kan omfatte askorbinsyre eller en farmasøytisk akseptabel forbindelse av askorbinsyre. En syre i den effervesente blandingen kan omfatte sitronsyre eller en farmasøytisk akseptabel forbindelse av sitronsyre. An acid in the effervescent mixture may comprise ascorbic acid or a pharmaceutically acceptable compound of ascorbic acid. An acid in the effervescent mixture may comprise citric acid or a pharmaceutically acceptable compound of citric acid.
Eksempel 1 Example 1
Sammensetning av effervesent sugetablett i henhold til oppfinnelsen Composition of effervescent lozenge according to the invention
Tablettvekt 750 mg Tablet weight 750 mg
Sammensetning pr. tablett Composition per tablet
Askorbinsyre (C-vitamin) 250 mg Ascorbic acid (vitamin C) 250 mg
P28090NO01 beskrivelse og krav, prioritetsdannende med prioritet P28090NO01 description and requirements, priority forming with priority
Pyridoksin (Vitamin B6) 10 mg Polyvinylpyrrolidon (PVP) 3% 22,5 mg Glukose 15 % 112,5 mg Sitronsyremonohydrat 104 mg Tartarsyre 111,4 mg Natriumbikarbonat (Natron) 124,6 mg PEG 8000 (Polyetylenglykol) 15 mg Pyridoxine (Vitamin B6) 10 mg Polyvinylpyrrolidone (PVP) 3% 22.5 mg Glucose 15% 112.5 mg Citric acid monohydrate 104 mg Tartaric acid 111.4 mg Sodium bicarbonate (Baking soda) 124.6 mg PEG 8000 (Polyethylene glycol) 15 mg
Eksempel 2 Example 2
Sammensetning av effervesent sugetablett i henhold til oppfinnelsen. Tabletten inneholder 1000 mg askorbinsyre. Composition of effervescent lozenge according to the invention. The tablet contains 1000 mg of ascorbic acid.
Vekt pr. tablett 4,3 g Størrelse (diameter) 25 mm Weight per tablet 4.3 g Size (diameter) 25 mm
Syre: L-askorbinsyre C6H8O6|Acid: L-ascorbic acid C6H8O6|
Sitronsyre C6H8O7Citric acid C6H8O7
pH-regulator: Natriumbikarbonat NaHCO3pH regulator: Sodium bicarbonate NaHCO3
Fuktmiddel: Sorbitol C6H14O6Humectant: Sorbitol C6H14O6
Maltodextrin C6nH(10n+2)O(5n+1)Maltodextrin C6nH(10n+2)O(5n+1)
pH-regulator Natriumkarbonat Na2CO3pH regulator Sodium carbonate Na2CO3
Anti klumpemiddel Trikalsiumfosfat Ca3(PO4)2Anti-caking agent Tricalcium phosphate Ca3(PO4)2
Fyllstoff Stivelse (C6H10O5)nFiller Starch (C6H10O5)n
Smaksstoff Flavoring agent
Søtningsstoff Sukralose C12H19Cl3O8Sweetener Sucralose C12H19Cl3O8
Rødbetsaftpulver (maltodekstrin, rødbetsaftpulver) Beetroot juice powder (maltodextrin, beetroot juice powder)
Fargestoff riboflavin 5’-fosfat-natrium C17H21N4O9P (Na) Dye riboflavin 5'-phosphate-sodium C17H21N4O9P (Na)
Det bør bemerkes at alle de ovennevnte utførelsesformene illustrerer oppfinnelsen, men begrenser den ikke, og fagpersoner på området vil kunne utforme mange alternative utførelsesformer uten å avvike fra omfanget av de vedlagte kravene. I kravene skal referansenumre i parentes ikke sees som begrensende. It should be noted that all of the above embodiments illustrate the invention, but do not limit it, and those skilled in the art will be able to devise many alternative embodiments without departing from the scope of the appended claims. In the requirements, reference numbers in parentheses should not be seen as limiting.
Bruken av verbet "å omfatte" og dets ulike former ekskluderer ikke tilstedeværelsen av elementer eller trinn som ikke er nevnt i kravene. De ubestemte artiklene "en", "ei" eller "et" foran et element ekskluderer ikke tilstedeværelsen av flere slike elementer. The use of the verb "to comprise" and its various forms does not exclude the presence of elements or steps not mentioned in the claims. The indefinite articles "an", "ei" or "et" before an element do not exclude the presence of several such elements.
Det faktumet at enkelte trekk er anført i innbyrdes forskjellige avhengige krav, indikerer ikke at en kombinasjon av disse trekkene ikke med fordel kan brukes. The fact that certain features are listed in different mutually dependent claims does not indicate that a combination of these features cannot be advantageously used.
P28090NO01 beskrivelse og krav, prioritetsdannende med prioritet P28090NO01 description and requirements, priority forming with priority
Claims (8)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NO2017/050332 WO2018117855A1 (en) | 2016-12-20 | 2017-12-19 | Effervescent lozenge |
| NO20190883A NO20190883A1 (en) | 2016-12-20 | 2019-07-12 | Effervescent lozenge |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20162027 | 2016-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20171457A1 true NO20171457A1 (en) | 2018-06-21 |
Family
ID=63012642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20171457A NO20171457A1 (en) | 2016-12-20 | 2017-09-08 | Effervescent lozenge |
| NO20190883A NO20190883A1 (en) | 2016-12-20 | 2019-07-12 | Effervescent lozenge |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20190883A NO20190883A1 (en) | 2016-12-20 | 2019-07-12 | Effervescent lozenge |
Country Status (1)
| Country | Link |
|---|---|
| NO (2) | NO20171457A1 (en) |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1505738A (en) * | 1975-02-26 | 1978-03-30 | Kirby Pharmaceuticals Ltd | Tabletting processes |
| BG102462U (en) * | 1998-05-19 | 1999-12-30 | Farmatsija Ad | Pharmaceutical composition |
| US20030170301A1 (en) * | 2002-03-11 | 2003-09-11 | Fred Wehling | Effervescent composition including stevia |
| AU2004242477A1 (en) * | 1999-03-26 | 2005-01-27 | Cima Labs Inc. | Sublingual buccal effervescent |
| WO2009047321A2 (en) * | 2007-10-10 | 2009-04-16 | Altergon S.A. | A sublingual effervescent tablet of progesterone associated with cyclodextrin |
| US20110014132A1 (en) * | 2009-07-14 | 2011-01-20 | Shuang Peter Liu | Solid effervescent mixture for the oral absorption |
| US20110223115A1 (en) * | 1998-03-27 | 2011-09-15 | Cima Labs Inc. | Sublingual buccal effervescent |
| US20130108745A1 (en) * | 2010-07-01 | 2013-05-02 | Delante Health As | Coated effervescent tablet |
| US20140294990A1 (en) * | 2013-03-27 | 2014-10-02 | Timothy P. O'Connor | Throat gargle tablet and method of use thereof |
| CN104434863A (en) * | 2014-11-13 | 2015-03-25 | 武汉大学 | Tetracaine hydrochloride oral effervescent tablet and preparation method thereof |
| NO338567B1 (en) * | 2003-12-31 | 2016-09-05 | Cima Labs Inc | Coarse oral dosage form for opiate oxycodone, and its use as a drug and in the treatment of pain |
| NO338714B1 (en) * | 2003-12-31 | 2016-10-03 | Cima Labs Inc | Generally linear, effervescent oral fentanyl dosage form suitable for administration of fentanyl over a patient's oral mucosa by buccal, gingival or sublingual administration, and methods of preparation thereof. |
| CN106539778A (en) * | 2016-12-08 | 2017-03-29 | 武汉大学 | Preoperative buccal oral cavity effervescent tablet of a kind of pediatric anesthesia and preparation method thereof |
-
2017
- 2017-09-08 NO NO20171457A patent/NO20171457A1/en not_active Application Discontinuation
-
2019
- 2019-07-12 NO NO20190883A patent/NO20190883A1/en not_active Application Discontinuation
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1505738A (en) * | 1975-02-26 | 1978-03-30 | Kirby Pharmaceuticals Ltd | Tabletting processes |
| US20110223115A1 (en) * | 1998-03-27 | 2011-09-15 | Cima Labs Inc. | Sublingual buccal effervescent |
| BG102462U (en) * | 1998-05-19 | 1999-12-30 | Farmatsija Ad | Pharmaceutical composition |
| AU2004242477A1 (en) * | 1999-03-26 | 2005-01-27 | Cima Labs Inc. | Sublingual buccal effervescent |
| US20030170301A1 (en) * | 2002-03-11 | 2003-09-11 | Fred Wehling | Effervescent composition including stevia |
| NO338567B1 (en) * | 2003-12-31 | 2016-09-05 | Cima Labs Inc | Coarse oral dosage form for opiate oxycodone, and its use as a drug and in the treatment of pain |
| NO338714B1 (en) * | 2003-12-31 | 2016-10-03 | Cima Labs Inc | Generally linear, effervescent oral fentanyl dosage form suitable for administration of fentanyl over a patient's oral mucosa by buccal, gingival or sublingual administration, and methods of preparation thereof. |
| WO2009047321A2 (en) * | 2007-10-10 | 2009-04-16 | Altergon S.A. | A sublingual effervescent tablet of progesterone associated with cyclodextrin |
| US20110014132A1 (en) * | 2009-07-14 | 2011-01-20 | Shuang Peter Liu | Solid effervescent mixture for the oral absorption |
| US20130108745A1 (en) * | 2010-07-01 | 2013-05-02 | Delante Health As | Coated effervescent tablet |
| US20140294990A1 (en) * | 2013-03-27 | 2014-10-02 | Timothy P. O'Connor | Throat gargle tablet and method of use thereof |
| CN104434863A (en) * | 2014-11-13 | 2015-03-25 | 武汉大学 | Tetracaine hydrochloride oral effervescent tablet and preparation method thereof |
| CN106539778A (en) * | 2016-12-08 | 2017-03-29 | 武汉大学 | Preoperative buccal oral cavity effervescent tablet of a kind of pediatric anesthesia and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20190883A1 (en) | 2019-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008040534A3 (en) | Non-mucoadhesive film dosage forms | |
| ES2534245T3 (en) | Antiviral Supplement Formulations | |
| JP2023519158A (en) | antiviral compound | |
| RU2255736C2 (en) | Zolmitriptan-containing pharmaceutical composition | |
| ES2954361T3 (en) | Methods of using dipivefrin | |
| ES2436037T3 (en) | Nasal spray or nasal drops for the treatment of the common cold | |
| CA2891362C (en) | Effervescent tablet | |
| MXPA00010598A (en) | Therapeutic anti-cold agent containing isomalt as an active ingredient. | |
| EP3618826B1 (en) | Compositions for the treatment of pathogenic infections | |
| EP1703901B1 (en) | Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol | |
| JP6491191B2 (en) | Lozenges for the treatment of sore throat, hoarseness and related dry cough, and inflammatory diseases of the oral cavity and pharyngeal cavity | |
| NO20171457A1 (en) | Effervescent lozenge | |
| WO2018117855A1 (en) | Effervescent lozenge | |
| ES2244333A1 (en) | Stable oral pharmaceutical preparation comprising fosfomycin, which is intended for diabetic patients | |
| JP4871497B2 (en) | DFA-containing poorly absorbed water-soluble physiologically active substance absorption promoter. | |
| US6548554B1 (en) | Ionic aqueous composition containing levomenthol | |
| US11878032B2 (en) | Aqueous saline composition, process for the production of same, and use of same | |
| US20070092552A1 (en) | Chewable lozenge cold remedy composition and method for making same | |
| EP4368178A1 (en) | Compositions of honey and gluconic acid and uses therefor | |
| WO2022154772A1 (en) | Anti-viral agent used in upper respiratory tract viral infections and the pharmaceutical composition comprising the same | |
| WO2004098571A1 (en) | Cold remedy composition comprising zinc salts | |
| EA023654B1 (en) | Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough | |
| WO2016021975A1 (en) | Method for preparing sublingual spray containing pde-5 inhibitor, and composition for sublingual spraying prepared thereby | |
| Ericson | Geranium Extract vs HIV/AIDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |